Mobile

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-023512-13

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Efficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis over 12 weeks based on PASI and IGA

Critère d'inclusion

  • Moderate to severe chronic plaque-type psoriasis

Liens